European Commission clears P&G, Merck deal | Progresiv
The European competition regulator has unconditionally approved Procter & Gamble’s proposed 3.4 billion euros acquisition of Merck’s consumer health unit. 
In its ruling, the European Commission said a preliminary review found that the deal “would raise no competition concerns because the activities of the companies are generally complementary. The transaction gives rise to a limited number of horizontal overlaps for which the Commission found, following its market investigation, that sufficient competition will remain after the transaction”.
The deal, announced in April 2018, will see P&G add brands such as Seven Seas, Femibion, Nasivin, and Kytta to its portfolio. It also significantly expands P&G’s presence in the emerging markets of Asia and Latin America. Around 3,300 Merck staff will also be transferred to P&G following the completion of the deal. (www.kamcity.com)
